STAT+: Lilly’s obesity pill cuts 15% of weight at highest dose in mid-stage trial
SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on…
Category: Pharmaceuticals
‘We fail people’: New data on disparities in Medicaid access to opioid addiction treatment
An estimated 82,998 people died from opioid overdoses in the U.S. last year. A new…
STAT+: Pharmalittle: FDA approves first gene therapy for Duchenne muscular dystrophy; states join FTC to stop Amgen deal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: GSK settles first lawsuit set for a U.S. trial over cancer links to Zantac
GSK reached a settlement with a man who claimed its Zantac heartburn medication caused his…
STAT+: FDA rejects Intercept’s NASH drug, prompting a pivot
The Food and Drug Administration rejected Intercept Pharmaceuticals’ investigational treatment for NASH on Thursday, derailing…
STAT+: Medicare puts out new details for covering the Alzheimer’s drug Leqembi, as the health system readies for potential approval
WASHINGTON — The health care system is on the precipice of broad access to a treatment…
STAT+: The strategy behind the pharmaceutical industry’s flurry of lawsuits challenging drug pricing reform
WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere….
STAT+: Pharmalittle: Europe regulator raised safety signal on Novo drugs; U.S. seeks new trial over royalties on Gilead HIV prevention pills
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: U.S. seeks a new trial over royalties on Gilead HIV prevention pills
The U.S. government asked a federal judge to overturn a recent case in which a…
Opinion: Former Surgeon General Jerome Adams: Prioritize new antivirals for Covid
The U.S. Covid-19 Public Health Emergency declaration may have ended, but the virus remains. Now is…
STAT+: European companies outline opposition to proposed overhaul of pharma policy
BRUSSELS — Leaders of European pharmaceutical companies on Wednesday said that a proposed overhaul of…
STAT+: Drug middlemen catch flak at another congressional hearing
Drug middlemen once again were on the hot seat at a congressional hearing on Wednesday….
STAT+: PhRMA sues Biden administration over Medicare drug price negotiation program
WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle…
Xylazine, or ‘tranq,’ is making opioid overdoses harder to reverse
For years, public health guidance about opioid overdoses has been relatively simple: Administer naloxone, then…
STAT+: Top federal lobbyist at PhRMA leaves
WASHINGTON — The top federal lobbyist for the brand drug lobby PhRMA is leaving, two…
.jpg)
STAT+: Novo Nordisk sues spas and clinics for selling versions of Wegovy and Ozempic for weight loss
In the latest fracas over obesity drugs, Novo Nordisk filed lawsuits alleging several medical spas,…
STAT+: ‘It’s beyond unethical’: Opaque conflicts of interest permeate prescription drug benefits
Employers across the country — from big names like Boeing and UPS to local school…
STAT+: How drug pricing reforms are affecting Bayer’s investments
WASHINGTON — Pharma companies have long been warning Democrats’ drug pricing reforms could discourage investment in…
STAT+: Trade group scolds drugmaker for ‘unethical’ attempt to gain info about rival product
In a notable move, a U.K. trade group has rebuked Leo Pharma for a “serious…
STAT+: Pharmalittle: FDA cites another troubled plant at company contributing to cancer drug shortages; USDA to push food producers over antibiotic claims
And so, another working week will soon draw to a close. Not a moment too…
White House ‘naloxone summit’ omitting prominent advocates for lower costs
The invite list for the White House’s upcoming “summit” on naloxone pricing and accessibility has…
STAT+: USDA to push food producers to substantiate claims that animals are raised without antibiotics
The U.S. Department of Agriculture is launching a program to ensure food producers substantiate claims…
STAT+: Pharmalittle: PBMs are targeted in yet another congressional bill; access to new Alzheimer’s drug may not happen quickly
Rise and shine, another busy day is on the way. However, this is also shaping…
Opinion: STAT+: How I’m helping companies think through whether they should cover GLP-1s like Ozempic for employees
We have a knack in the U.S. for blurring behavior and medicine. Look at weight….
STAT+: Pharmalittle: A not-so-new Biogen?; ALS Association and 15 chapters part ways over organizational clashes
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Bitter infighting leads 15 chapters to break away from leading ALS advocacy group
After a bitter dispute, the ALS Association has settled a lawsuit filed by 15 chapters…
AMA asks doctors to de-emphasize use of BMI in gauging health and obesity
CHICAGO – The American Medical Association on Tuesday strongly criticized the body-mass index, urging doctors…
STAT+: Sanders wants NIH to adopt ‘reasonable pricing’ language for drugs that agency research helps develop
In another bid to lower prescription drug prices, U.S. Sen. Bernie Sanders (I-Vt.) issued a…
STAT+: Pharmalittle: Exec nominated to Biogen board is mother of outgoing director’s child; telehealth company pauses Wegovy ads amid shortages
Top of the morning to you, and a fine one it is. Sunny skies and…
Ro pauses advertising of weight loss drug Wegovy amid shortages
Telehealth company Ro has paused advertising of the obesity drug Wegovy as the drug suffers…
STAT+: Pharmalittle: U.S. Chamber sues over Medicare price negotiations; FDA seeks new supplier for scarce cancer drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: FDA panel unanimously endorses Eisai’s Alzheimer’s drug
Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding…
STAT+: Tracking the FDA advisory panel on Eisai and Biogen’s treatment for Alzheimer’s disease
The Food and Drug Administration is convening a meeting of outside experts on Friday to…
STAT+: If AI invents a new medicine, who gets the patent?
Pharmaceutical and biotech companies are increasingly using artificial intelligence to discover and make drugs and…
BMI is starting to plateau in rich Western countries. That doesn’t mean obesity is solved
This is part of a series about new obesity drugs that are transforming patients’ lives,…
STAT+: Sen. Cassidy wants to put a stop to FDA delays in drug review process
WASHINGTON – Sen. Bill Cassidy (R-La.) is looking into ways to speed up the Food…
STAT+: ‘We don’t agree’ on drug pricing policy, FDA chief tells biotech leaders
BOSTON — The drug industry has spent the past year speaking against new mechanisms that…
STAT+: After missing vaccine glory in pandemic, GSK looks to dominate other diseases
BOSTON — GSK has been developing vaccines under one corporate guise or another for 140…
STAT+: ASCO showcased the payoff for new cancer medicines: longer lives
CHICAGO — Well, that’s a wrap. The biggest meeting in cancer research — and, really,…
STAT+: FDA will allow troubled chemotherapy maker to resume distribution of cancer drugs in short supply
After finding a “cascade of failures” at a manufacturing plant run by a key chemotherapy…
‘Tantamount to extortion:’ Merck sues U.S. government over Medicare negotiation program
WASHINGTON — Merck on Tuesday sued to stop the federal government from implementing a new…
STAT+: The woman behind AstraZeneca’s cancer winning streak
CHICAGO — It was the kind of moment scientists who develop new medicines wait their…
STAT+: FDA removes neurologist with financial ties to Eisai and Biogen from Alzheimer’s advisory panel
The Food and Drug Administration has removed a neurologist with financial ties to Biogen and…
STAT+: FDA oncology head wants advisory panels to keep voting on new drugs
CHICAGO — As commissioner of the Food and Drug Administration, Robert Califf has made clear…
STAT+: Ted Love, BIO’s first Black board chair, aims to rehab biotech’s image in Washington
WASHINGTON — Ted Love has pretty much done everything there is to do in biotech. He’s…
STAT+: To push antibiotic makers to be more green, a new system will certify manufacturing practices
In response to concerns about pollution caused by antibiotic production, an industry group is launching…
Akero’s NASH drug combined with Ozempic cut liver fat in small study
GLP-1s, a class of drugs including Ozempic and Wegovy that have become widely popular for…
STAT+: Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO
CHICAGO — The annual meeting of the American Society of Clinical Oncology is back in…
STAT+: Biotechs face challenges as the industry’s annual bash returns to Boston
The world has changed since 2018 when the Biotechnology Innovation Organization last brought its annual…
STAT+: ‘Extraordinary’ survival data for lung cancer patients is seen as boost for AstraZeneca drug
CHICAGO – Giving the AstraZeneca drug Tagrisso to patients with non-small cell lung cancer who…